SPRBSpruce Biosciences Inc
$50.74
$1.00
(1.93%)
Mkt Cap$142.4M
Vol30.00
Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at...
Business Wire
Spruce Biosciences Joins the Russell 3000 Index
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has been added as a member of the Russell 3000 Index, effective with the...
Business Wire
Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Agnieszka AJ Jurecka, M.D., Ph.D., MPH, as Vice President...
Business Wire
Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointments of Eric Jordan as Vice President, Marketing and Tina Gullotta...
Business Wire
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data demonstrating the long-term benefit of tralesinidase alfa enzyme...
Business Wire
Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data on the long-term administration of its tralesinidase alfa enzyme...
Business Wire
Spruce Biosciences to Participate in Upcoming Conferences in June
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that members of the management team will present and participate in one-on-one...
Business Wire
Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...
Business Wire
Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...
Business Wire
Spruce Biosciences (SPRB) Projected to Post Earnings on Tuesday
Spruce Biosciences (NASDAQ:SPRB) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest SPRB News
ViewSpruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
Business Wire
Spruce Biosciences Joins the Russell 3000 Index
Business Wire
Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs
Business Wire
Advertisement|Remove ads.